Nagashima Y.,Shakaihoken Shimonoseki Kosei Hospital |
Maeda N.,Yamaguchi University |
Yamamoto S.,Yamaguchi University |
Yoshino S.,Yamaguchi University |
Oka M.,Yamaguchi University
OncoTargets and Therapy | Year: 2013
Purpose: Anthracycline-based chemotherapies for breast cancer are well known to have adverse effects and can also negatively affect host immune function. There is therefore a necessity for an adjuvant that maintains the quality of life (QOL) and immune function of cancer patients receiving anthracycline-based chemotherapies. Patients and methods: The present study investigated the effectiveness of the concomitant use of Lentinula edodes mycelia extract (LEM), an oral immunomodulator, with FEC75 (5-fluorouracil + epirubicin + cyclophosphamide) therapy on host QOL and immune function in breast cancer patients with nodal metastases. Ten breast cancer patients with nodal metastases receiving surgery were enrolled in this study. Treatment with 5-fluorouracil (500 mg/m2), epirubicin (75 mg/m2), and cyclophosphamide (500 mg/m2) was performed every 21 days for two courses, and LEM (1800 mg/day by mouth) was administered during the second course. Results: In the first course, hematological toxicity was observed and host QOL and immune function were exacerbated. In the second course, however, the number of white blood cells and lymphocytes did not decrease and host QOL was maintained. Furthermore, the cytotoxic activities of natural killer (NK) and lymphokine-activated killer cells and the proportion of activated NK and NK T-cells in lymphocytes were maintained in the second course. Conclusion: It has been suggested that the concomitant use of LEM with FEC75 therapy can maintain host QOL and immune function, and offer important implications for an application of LEM as a useful oral adjuvant to anthracycline-based chemotherapies. © 2013 Nagashima et al, publisher and licensee Dove Medical Press Ltd.
Nakamura M.,Shakaihoken Shimonoseki Kosei Hospital
Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2012
A 77-year-old man complained chiefly of chest pain and heartburn. He had type 3 gastric cancer on the posterior wall of vestibular part. Distal partial gastrectomy and D2 lymph node dissection were performed. The pathological findings were as follows: partially poor tub2, pT2 (SS), ly2, v0, pN1, H0, P0, CY0, M0, pStage II,and Cur A. S-1 was administered orally as an adjuvant therapy. Carbohydrate antigen(CA) 19-9 levels were elevated 16 months after the operation. Computed tomography revealed a small amount of ascitic fluid with no other significant findings. Endoscopy revealed an erythrogenic protruding lesion 20 cm from the anal verge. In the biopsy, the lesion was classified as Group V, indicating metastasis of gastric cancer. It was judged that the S-1 therapy had led to the recurrence of peritoneal dissemination. Weekly paclitaxel (PTX; 3-week administration followed by 1-week withdrawal) was used together with doxifluridine(5'-DFUR; daily oral administration). CA19-9 levels decreased gradually, becoming normal in 3 months. Most of the ascitic fluid disappeared in 4 months. In the endoscopy performed after 9 months, the lesion was classified as Group I, revealing a histological complete response (CR). No serious side effects were observed, although epilation occurred as an adverse event. Currently, 21 months after the start of treatment, the CR has persisted. These results suggest that despite a few side effects, concomitant therapy with weekly PTX and 5'-DFUR can be continued as ambulatory care, and it may be effective in patients treated previously with S-1 who exhibit recurrence of peritoneal dissemination of gastric cancer.